Skuldtech becomes Acobiom

Published: 21-Jul-2014

Biomarker specialist changes its name to confirm its shift towards personalised medicine


Skuldtech, a French company that specialises in the discovery of genomic and transcriptomic biomarkers, and in the development of innovative diagnostics, has changed its name to Acobiom.

The new name is intended to confirm the company’s shift towards personalised medicine, which represents a major opportunity for medicines of the future.

Used in screening, diagnosis and in evaluating response to, or tolerance of, a targeted therapy, biomarkers are increasingly linked to the development and growth of the market for personalised medicine.

According to PricewaterhouseCoopers, the US market for personalised medicine is currently worth US$232bn. The therapeutics and diagnostics segment is expected to reach $42bn by 2015, with average growth of 10% a year.

In taking the name Acobiom, the Montpellier-based company, founded in 1999, seeks to promote and develop its companion diagnostics and its expertise in the discovery of new biomarkers. In the coming months it plans to bring new companion diagnostics to market and to launch clinical trials for cancer.

Acobiom has filed two cancer-related patents and expects to file a further two in the same thematic area by the end of the year.

'As the company turns 15, this new name represents a new avenue for us,' said Didier Ritter, Chairman and CEO of Acobiom. 'For all our staff and shareholders ‘Acobiom’ embodies the constant reinvention and enhancement of our position in personalised medicine, the medicine of tomorrow.'

Since it was formed, Acobiom has raised €1.5m from private investors. It has also received €1.3m in funding from French public investment bank Bpifrance for two projects developed in partnership with pharmaceutical company AB Science; investigating pancreatic cancer and Alzheimer’s disease.

The company is now seeking additional funding to finance its clinical trials.

You may also like